• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Invivyd Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    3/26/25 4:31:05 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IVVD alert in real time by email
    8-K
    false000183203800018320382025-03-222025-03-22

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): March 22, 2025

     

    Invivyd, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

     

     

    Delaware

    001-40703

    85-1403134

    (State or Other Jurisdiction

    of Incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

    1601 Trapelo Road, Suite 178

    Waltham, MA

    02451

    (Address of Principal Executive Offices)

    (Zip Code)

     

    Registrant’s telephone number, including area code: (781) 819-0080

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange

    on which registered

    Common stock, par value $0.0001 per share

    IVVD

    The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On March 22, 2025, the Board of Directors (the “Board”) of Invivyd, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Ajay Royan as a director, effective immediately, with his term expiring at the Company’s 2025 annual meeting of stockholders.

     

    Mr. Royan’s compensation as a director will be consistent with the compensation provided to all of the Company’s non-employee directors. Under the Company’s current non-employee director compensation policy, Mr. Royan will receive an annual cash retainer of $40,000 for his Board service. Mr. Royan was granted a nonqualified option to acquire 100,000 shares of common stock of the Company (the “Common Stock”), with such grant vesting over a three-year period, with one-third of the shares vesting on the first anniversary of March 24, 2025 (the “Grant Date”) and 1/36th of the total shares vesting in substantially equal monthly installments thereafter, such that the option is fully vested on the third anniversary of the Grant Date, subject to Mr. Royan’s continuous service with the Company through each such vesting date. The option is exercisable for 10 years from the Grant Date and has the same per share exercise price as the closing sales price of the Common Stock on the Nasdaq Stock Market on the Grant Date. The option is subject to the terms and conditions of the Company’s 2021 Equity Incentive Plan, as amended.

     

    The Company and Mr. Royan also entered into the Company’s standard form of indemnification agreement, a copy of which was filed as Exhibit 10.4 to the Company’s Annual Report on Form 10-K (File No. 001-40703) filed with the U.S. Securities and Exchange Commission on March 20, 2025. Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify each director for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts actually and reasonably incurred by them in any action or proceeding arising out of their service as a director of the Company.

     

    There is no arrangement or understanding between Mr. Royan and any other person pursuant to which Mr. Royan was appointed a director of the Company. There are no relationships or transactions in which Mr. Royan has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.

     

    Item 7.01 Regulation FD Disclosure.

     

    On March 26, 2025, the Company issued a press release announcing Mr. Royan’s appointment to the Board. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 7.01.

     

    Item 9.01

     

    Financial Statements and Exhibits.

     

    (d) Exhibits

     

     

     

    Exhibit
    No.

     

    Description

    99.1

     

    Press Release, dated March 26, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    INVIVYD, INC.

    Date: March 26, 2025

    By:

    /s/ Jill Andersen

    Jill Andersen

    Chief Legal Officer and Corporate Secretary

     

     


    Get the next $IVVD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IVVD

    DatePrice TargetRatingAnalyst
    12/22/2025$10.00Buy
    BTIG Research
    11/25/2025Buy → Hold
    D. Boral Capital
    10/6/2025$10.00Overweight
    Cantor Fitzgerald
    4/5/2024$9.00Neutral → Buy
    Guggenheim
    3/26/2024$4.00 → $10.00Equal-Weight → Overweight
    Morgan Stanley
    12/19/2023$1.00 → $4.00Underweight → Equal-Weight
    Morgan Stanley
    5/1/2023$5.00Buy
    H.C. Wainwright
    More analyst ratings

    $IVVD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Allen Robert D. Iii converted options into 99,000 shares and sold $58,600 worth of shares (37,581 units at $1.56), increasing direct ownership by 116% to 114,487 units (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    2/18/26 8:56:34 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Human Resources Officer Green Julie converted options into 99,000 shares and sold $63,350 worth of shares (40,627 units at $1.56), increasing direct ownership by 118% to 107,717 units (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    2/18/26 8:51:23 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Duke William E. converted options into 99,000 shares and sold $63,350 worth of shares (40,627 units at $1.56), increasing direct ownership by 118% to 107,717 units (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    2/18/26 8:49:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

    Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025DECLARATION trial on track with full enrollment achievedDECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC re

    3/5/26 7:03:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

    Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital, Dr. Mina strengthens Invivyd's medical leadership Dr. Mina's research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipelineWith more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and conveying its meaning and impact to healthc

    3/5/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

    NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company's investor rel

    3/2/26 4:10:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Invivyd with a new price target

    BTIG Research initiated coverage of Invivyd with a rating of Buy and set a new price target of $10.00

    12/22/25 8:39:25 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd downgraded by D. Boral Capital

    D. Boral Capital downgraded Invivyd from Buy to Hold

    11/25/25 8:11:06 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cantor Fitzgerald initiated coverage on Invivyd with a new price target

    Cantor Fitzgerald initiated coverage of Invivyd with a rating of Overweight and set a new price target of $10.00

    10/6/25 8:27:43 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    SEC Filings

    View All

    SEC Form 10-K filed by Invivyd Inc.

    10-K - Invivyd, Inc. (0001832038) (Filer)

    3/5/26 7:20:57 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

    8-K - Invivyd, Inc. (0001832038) (Filer)

    3/5/26 7:11:42 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Invivyd Inc.

    144 - Invivyd, Inc. (0001832038) (Subject)

    2/17/26 6:30:21 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mclaughlin Kevin F bought $125,000 worth of shares (50,000 units at $2.50) (SEC Form 4)

    4 - Invivyd, Inc. (0001832038) (Issuer)

    11/20/25 4:22:07 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Financials

    Live finance-specific insights

    View All

    Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

    Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025DECLARATION trial on track with full enrollment achievedDECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC re

    3/5/26 7:03:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

    NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 5, 2026, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link. Analysts wishing to participate in the question-and-answer session should use this link. Those who plan on participating are advised to join 15 minutes prior to the start time. A recording of the webcast will be available on the company's investor rel

    3/2/26 4:10:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

    NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, November 6, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a corporate update. Interested parties may join the live webcast by visiting this link and are advised to log in approximately 15 minutes prior to the start of the call. A recording of the webcast will be available on the company's investor relations website shortly after the event. About Invivyd Invivyd, Inc. (NASDAQ:IVVD) is a biopharmaceutical c

    11/3/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Leadership Updates

    Live Leadership Updates

    View All

    Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

    Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital, Dr. Mina strengthens Invivyd's medical leadership Dr. Mina's research at Harvard focused on antibodies, vaccines, and infectious diseases with special expertise in COVID-19, measles, and other diseases, and will be a significant asset to Invivyd and the advancement of its pipelineWith more than 100 scientific publications and 10,000 citations, as well as hundreds of popular press interviews and op-eds, Dr. Mina is an expert in conducting research and conveying its meaning and impact to healthc

    3/5/26 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

    NEW HAVEN, Conn., Oct. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: Invivyd, Inc. (NASDAQ:IVVD) is hosting the previously announced live webcast to present an overview of the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine-alternative monoclonal antibody candidate for the prevention of COVID. The session will feature key members of the Invivyd team. WHEN: Thursday, October 30, 2025, at 8:30 a.m. ET WHERE: Listeners are advised to join the webcast via the following link 15 minutes prior to the start time. A replay of the webcast will be available via the investor relations section of the company's website approximately two hours after the conclusion of

    10/28/25 7:01:00 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

    NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. "We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases," said Marc Elia, Chairman of the Board of Invivyd. "Dr. Bolno's extensive experience in leading Wave Life Sciences through rapid pipeline developm

    9/24/25 4:01:00 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IVVD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Invivyd Inc.

    SC 13D/A - Invivyd, Inc. (0001832038) (Subject)

    12/12/24 4:39:09 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

    SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

    11/14/24 4:30:58 PM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

    SC 13G/A - Invivyd, Inc. (0001832038) (Subject)

    11/14/24 9:16:35 AM ET
    $IVVD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care